KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) EBT (2016 - 2025)

Historic EBT for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $147.2 million.

  • BeOne Medicines' EBT rose 24970.3% to $147.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.3 million, marking a year-over-year increase of 12282.78%. This contributed to the annual value of -$533.0 million for FY2024, which is 3545.92% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' EBT is $147.2 million, which was up 24970.3% from $99.5 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' EBT ranged from a high of $229.3 million in Q3 2023 and a low of -$606.0 million during Q4 2021
  • Over the past 5 years, BeOne Medicines' median EBT value was -$336.9 million (recorded in 2023), while the average stood at -$237.4 million.
  • Its EBT has fluctuated over the past 5 years, first crashed by 78091.65% in 2022, then surged by 24970.3% in 2025.
  • BeOne Medicines' EBT (Quarter) stood at -$606.0 million in 2021, then rose by 28.89% to -$431.0 million in 2022, then increased by 18.61% to -$350.8 million in 2023, then surged by 75.67% to -$85.4 million in 2024, then soared by 272.42% to $147.2 million in 2025.
  • Its EBT was $147.2 million in Q3 2025, compared to $99.5 million in Q2 2025 and $20.9 million in Q1 2025.